Seeking Alpha

Geron (GERN -4.3%) looks like it will be unable to use its imetelstat drug for treating...

Geron (GERN -4.3%) looks like it will be unable to use its imetelstat drug for treating lung-cancer patients after final results from a Phase II study confirm that the medicine was ineffective in a sub-group of patients in which initial results had looked promising. (PR)
Comments (1)
  • k6md
    , contributor
    Comment (1) | Send Message
     
    makes absolutely no sense in the face of the strong basic science----experimental set-up for failure????????????
    10 Apr 2013, 01:50 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|